Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.79 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.79 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.64 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26216797 | 0.90 | L3MBTL3 (0.93) | L3MBTL3L3MBTL1L3MBTL4HRH3MBTD1 | |
| SCHEMBL23682640 | 0.88 | L3MBTL3 (1.00) | L3MBTL3L3MBTL1L3MBTL4MBTD1 | |
| SCHEMBL3767275 | 0.86 | L3MBTL3 (0.66) | L3MBTL3L3MBTL1L3MBTL4HRH3MBTD1 | |
| SCHEMBL1964003 | 0.85 | L3MBTL4 (0.69) | L3MBTL3L3MBTL1L3MBTL4HSD17B10ALDH1A1 | |
| SCHEMBL14991641 | 0.82 | L3MBTL3 (0.74) | L3MBTL3L3MBTL1L3MBTL4HSD17B10ALDH1A1 | |
| SCHEMBL18734159 | 0.81 | L3MBTL3 (0.72) | L3MBTL3L3MBTL1L3MBTL4HSD17B10ALDH1A1 | |
| SCHEMBL3037311 | 0.79 | HRH3 (0.69) | L3MBTL3L3MBTL1L3MBTL4HRH3KCNH2 | |
| SCHEMBL4172189 | 0.79 | HRH3 (0.58) | L3MBTL3L3MBTL1L3MBTL4HRH3KCNH2 | |
| SCHEMBL4166733 | 0.79 | HRH3 (0.60) | L3MBTL3L3MBTL1L3MBTL4HRH3KCNH2 | |
| SCHEMBL4169908 | 0.78 | HRH3 (0.59) | L3MBTL3L3MBTL1L3MBTL4HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220045-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009067406-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-28 | — | — | WO | disclosed |
| US-20090131417-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131417-A1 | SUBSTITUTED PYRIDYL AMIDE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | L3MBTL3 3191/4885L3MBTL1 2849/4885L3MBTL4 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.